Physician profile
Andrew U So
NPI 1063679330
$2,950.01
in general payments reported to CMS, 2019-2025
17 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $120 · 2021: $338 · 2022: $431 · 2023: $584 · 2024: $458 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,821.47 | 2019-2024 | Xarelto |
| Philips North America LLC | $317.43 | 2022-2025 | (Ck4) Mcot, Event |
| Janssen Biotech, INC. | $226.10 | 2024-2025 | Tremfya, Stelara |
| Medtronic, INC. | $150.65 | 2025 | Linq II, Mycarelink |
| Biotronik Nro, INC. | $72.00 | 2023-2025 | Prospera, Biotronik |
| Alnylam Pharmaceuticals INC. | $68.90 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $62.17 | 2025 | |
| Abbott Laboratories | $42.16 | 2024 | Merlin@Home |
| Novartis Pharmaceuticals Corporation | $30.15 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.25 | 2025 | Lifevest |
| Novo Nordisk INC | $23.80 | 2025 | Ozempic |
| Amgen INC. | $20.71 | 2025 | Repatha |
| Baxter Healthcare | $20.63 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Inspire Medical Systems, INC. | $18.93 | 2025 | Inspire |
| Medtronic Vascular, INC. | $18.34 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16.61 | 2021 | |
| Abbvie INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.